BeOne Medicines Ltd.
ONC
$308.63
-$5.04-1.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 178.34% | 100.51% | 58.27% | -175.63% | 68.41% |
| Total Depreciation and Amortization | 25.73% | 31.19% | 99.00% | -14.36% | 10.51% |
| Total Amortization of Deferred Charges | 388.45% | -0.85% | 26.48% | -40.04% | 40.12% |
| Total Other Non-Cash Items | 13.25% | 21.19% | 6.64% | 120.41% | 13.02% |
| Change in Net Operating Assets | 104.72% | 49.78% | 57.58% | -20.64% | -220.96% |
| Cash from Operations | 375.76% | 114.29% | 128.21% | 17.40% | 67.47% |
| Capital Expenditure | 60.14% | 63.98% | 29.86% | 15.12% | 9.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,005.27% | -23.06% | 25.10% | -38.16% | -100.57% |
| Cash from Investing | 40.01% | 41.89% | 26.86% | -90.51% | -263.76% |
| Total Debt Issued | -22.40% | -47.05% | 9.62% | 908.00% | 2.68% |
| Total Debt Repaid | 31.25% | -4,849.32% | -261.30% | 91.11% | -1,010.88% |
| Issuance of Common Stock | 495.69% | 328.36% | 235.15% | 23.03% | 55.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 6.81% | -- |
| Other Financing Activities | -906.50% | -- | 20.99% | -23.88% | -- |
| Cash from Financing | 52.17% | -120.81% | -92.11% | 86.71% | -86.14% |
| Foreign Exchange rate Adjustments | 497.78% | 115.51% | -250.16% | -54.60% | 90.51% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 234.82% | 71.43% | 57.59% | 11.18% | -55.09% |